Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Hydroxyethyl starch (HES) is commonly used as plasma expander during surgery but may be nephrotoxic as seen in studies in patients with sepsis. The investigators hypothesized that the possible nephrotoxicity of 6% HES 130/0.4 could be revealed by measurements of urinary and plasma neutrophil gelatinase-associated lipocalin and interleukin-18 (IL-18) in old patients with normal renal function during orthopaedic surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuanyuan Zhang
• Collaborators: Tianjin First Central Hospital; Tianjin Union Medical Center
• Treatments: Hydroxyethyl Starch Derivatives

Criteria

Inclusion Criteria:

• Old patients scheduled to undergo orthopaedic surgery under a intravertebral anesthesia. (American Society of Anesthesiologists physical status I-Ⅲ)

Exclusion Criteria:

• Allergy and contraindication to HES

• Infections and malignancies

• Sepsis

• History of heart failure or New York Heart Association(NYHA)>Ⅲ

• Renal failure or Cr>108μmol/L，BUN>8.3mmol/L

• Undergoing dialytic treatments

• Intracranial hemorrhages

• Taking non-steroidal antiinflammatory agent for a long time

• Inability to understand the Study Information Sheet and provide a written consent to take part in the study